Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference

On May 17, 2022 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, reported that Company’s Management will provide a corporate update and participate virtually in one-on-one investor meetings at the H.C. Wainwright Global Investment Conference, to be held virtually and in Miami, Florida from May 23-26, 2022 (Press release, Selecta Biosciences, MAY 17, 2022, View Source [SID1234614722]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.